News

RPL554 is a novel inhaled PDE3/PDE4 inhibitor with both bronchodilator and anti-inflammatory properties in the same molecule, currently in development as a nebulised treatment for acute exacerbations in

After completion of the acquisition, including the agreed upon transition period, Orexigen will hold all rights to Contrave in almost all territories globally. The companies have agreed to

The approval was based on its bioequivalence to the standard melphalan formulation (Alkeran) in a phase 2 clinical study. Evomela has been granted Orphan Drug Designation by the

The treatment is for patients with locally advanced or metastatic urothelial carcinoma (mUC) who had disease progression during or after platinum-based chemotherapy in the metastatic setting, or whose

The trial is a double-blind, placebo-controlled, three arm, multicenter study enrolling approximately 350 patients with Lactose Intolerance symptoms. Patients will undergo a 30-day treatment process, followed by a

The Prescription Drug User Fee Act (PDUFA) action date for completion of FDA review of the eteplirsen is May 26, 2016. The FDA has granted eteplirsen Priority Review

This is the second orphan drug designation obtained by ProNAi for PNT2258 for the treatment of DLBCL, following a similar grant by the European Commission in August 2015.

Aeglea plans to start a phase 1 dose escalation study in the first half of this year in patients with relapsed and refractory acute myeloid leukemia (AML) and

In the phase 3 study of 309 patients with secondary, or high risk, acute myeloid leukemia, those who received Vyxeos on average lived for 9.56 months after the